{"id":264,"date":"2024-08-28T13:43:15","date_gmt":"2024-08-28T05:43:15","guid":{"rendered":"https:\/\/flcube.com\/?p=264"},"modified":"2024-10-13T18:04:55","modified_gmt":"2024-10-13T10:04:55","slug":"walvax-biotechnology-reports-2024h1-revenue-dip-amid-intense-vaccine-market-competition","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=264","title":{"rendered":"Walvax Biotechnology Reports 2024H1 Revenue Dip Amid Intense Vaccine Market Competition"},"content":{"rendered":"\n

Walvax Biotechnology Co., Ltd, a Chinese vaccine manufacturer listed on the Shenzhen Stock Exchange (SHE: 300142<\/a>), has released its financial report for the first half of 2024. The company reported operating revenue of RMB 1.433 billion, marking a significant year-on-year (YOY) decrease of 33.88%. The non-net profit attributable to the parent company was RMB 146 million, a substantial YOY decline of 65.39%. Total assets at the period’s end were recorded at RMB 15.086 billion, a slight YOY reduction of 3.22%.<\/p>\n\n\n\n

Walvax commercializes a portfolio of 8 self-developed vaccines, including the 13-valent pneumococcal conjugate vaccine, bivalent HPV vaccine, 23-valent pneumococcal polysaccharide vaccine, Haemophilus influenzae type b conjugate vaccine, Group A and C meningococcal polysaccharide conjugate vaccine, ACYW135 meningococcal polysaccharide vaccine, Group A and C meningococcal polysaccharide vaccine, and adsorbed acellular pertussis combined vaccine. Notably, its COVID-19 mRNA vaccine, targeting the Omicron XBB.1.5 variant, has received emergency use authorization in China. Throughout the period, a total of 13,840,764 doses of Walvax’s marketed vaccines were approved for distribution. The 13-valent pneumococcal conjugate vaccine retains its leading market share in China, and the bivalent HPV vaccine has seen volume growth through the Huiminbao project.<\/p>\n\n\n\n

The company’s revenue, 95.34% of which was generated from the production and sales of its vaccine products in the first half of the year, has been impacted by intensified industry competition and demographic and consumption habit shifts in the domestic market. Despite these challenges, Walvax has expanded its reach to overseas markets, with H1 2024 sales reaching a record high of RMB 299.81 million. Additionally, the company is progressing in the development of its nine-valent HPV vaccine, with its Phase III clinical trial well underway.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Walvax Biotechnology Co., Ltd, a Chinese vaccine manufacturer listed on the Shenzhen Stock Exchange (SHE:…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,1152,12,332],"class_list":["post-264","post","type-post","status-publish","format-standard","hentry","category-company","tag-finanical-reports","tag-she-300142","tag-vaccine","tag-walvax-biotechnology"],"yoast_head":"\nWalvax Biotechnology Reports 2024H1 Revenue Dip Amid Intense Vaccine Market Competition - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Walvax Biotechnology Co., Ltd, a Chinese vaccine manufacturer listed on the Shenzhen Stock Exchange (SHE: 300142), has released its financial report for the first half of 2024. The company reported operating revenue of RMB 1.433 billion, marking a significant year-on-year (YOY) decrease of 33.88%. The non-net profit attributable to the parent company was RMB 146 million, a substantial YOY decline of 65.39%. Total assets at the period's end were recorded at RMB 15.086 billion, a slight YOY reduction of 3.22%.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=264\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Walvax Biotechnology Reports 2024H1 Revenue Dip Amid Intense Vaccine Market Competition\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=264\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-28T05:43:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-13T10:04:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=264#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=264\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Walvax Biotechnology Reports 2024H1 Revenue Dip Amid Intense Vaccine Market Competition\",\"datePublished\":\"2024-08-28T05:43:15+00:00\",\"dateModified\":\"2024-10-13T10:04:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=264\"},\"wordCount\":279,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Finanical Reports\",\"SHE: 300142\",\"Vaccine\",\"Walvax Biotechnology\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=264#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=264\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=264\",\"name\":\"Walvax Biotechnology Reports 2024H1 Revenue Dip Amid Intense Vaccine Market Competition - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-08-28T05:43:15+00:00\",\"dateModified\":\"2024-10-13T10:04:55+00:00\",\"description\":\"Walvax Biotechnology Co., Ltd, a Chinese vaccine manufacturer listed on the Shenzhen Stock Exchange (SHE: 300142), has released its financial report for the first half of 2024. The company reported operating revenue of RMB 1.433 billion, marking a significant year-on-year (YOY) decrease of 33.88%. The non-net profit attributable to the parent company was RMB 146 million, a substantial YOY decline of 65.39%. Total assets at the period's end were recorded at RMB 15.086 billion, a slight YOY reduction of 3.22%.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=264#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=264\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=264#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Walvax Biotechnology Reports 2024H1 Revenue Dip Amid Intense Vaccine Market Competition\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Walvax Biotechnology Reports 2024H1 Revenue Dip Amid Intense Vaccine Market Competition - Insight, China's Pharmaceutical Industry","description":"Walvax Biotechnology Co., Ltd, a Chinese vaccine manufacturer listed on the Shenzhen Stock Exchange (SHE: 300142), has released its financial report for the first half of 2024. The company reported operating revenue of RMB 1.433 billion, marking a significant year-on-year (YOY) decrease of 33.88%. The non-net profit attributable to the parent company was RMB 146 million, a substantial YOY decline of 65.39%. Total assets at the period's end were recorded at RMB 15.086 billion, a slight YOY reduction of 3.22%.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=264","og_locale":"en_US","og_type":"article","og_title":"Walvax Biotechnology Reports 2024H1 Revenue Dip Amid Intense Vaccine Market Competition","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=264","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-08-28T05:43:15+00:00","article_modified_time":"2024-10-13T10:04:55+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=264#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=264"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Walvax Biotechnology Reports 2024H1 Revenue Dip Amid Intense Vaccine Market Competition","datePublished":"2024-08-28T05:43:15+00:00","dateModified":"2024-10-13T10:04:55+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=264"},"wordCount":279,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Finanical Reports","SHE: 300142","Vaccine","Walvax Biotechnology"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=264#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=264","url":"https:\/\/flcube.com\/?p=264","name":"Walvax Biotechnology Reports 2024H1 Revenue Dip Amid Intense Vaccine Market Competition - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-08-28T05:43:15+00:00","dateModified":"2024-10-13T10:04:55+00:00","description":"Walvax Biotechnology Co., Ltd, a Chinese vaccine manufacturer listed on the Shenzhen Stock Exchange (SHE: 300142), has released its financial report for the first half of 2024. The company reported operating revenue of RMB 1.433 billion, marking a significant year-on-year (YOY) decrease of 33.88%. The non-net profit attributable to the parent company was RMB 146 million, a substantial YOY decline of 65.39%. Total assets at the period's end were recorded at RMB 15.086 billion, a slight YOY reduction of 3.22%.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=264#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=264"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=264#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Walvax Biotechnology Reports 2024H1 Revenue Dip Amid Intense Vaccine Market Competition"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/264","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=264"}],"version-history":[{"count":4,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/264\/revisions"}],"predecessor-version":[{"id":5871,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/264\/revisions\/5871"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=264"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}